- Home
- NMI vs ANIX Comparison
NMI vs ANIX Comparison
Compare NMI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | ANIX |
|---|---|---|
| Founded | 1988 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.0M | 135.3M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | NMI | ANIX |
|---|---|---|
| Price | $9.97 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 28.4K | ★ 448.6K |
| Earning Date | 01-01-0001 | 01-09-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $2.07 |
| 52 Week High | $10.05 | $5.46 |
Technical Indicators
Market Signals| Indicator | NMI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 36.80 |
| Support Level | $9.93 | $3.23 |
| Resistance Level | $10.03 | $3.44 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 28.00 | 2.78 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.